A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy

Vaccine

Volumn 27, Issue 35, 2009, Pages 4826-4833

  Alvarez Rueda, Nidia ^a   Ladjemi, Maha Zohra ^a   Béhar, Ghislaine ^b   Corgnac, Stéphanie ^a   Pugnière, Martine ^c   Roquet, Françoise ^c   Bascoul Mollevi, Caroline ^d   Baty, Daniel ^b   Pèlegrin, André ^a   Navarro Teulon, Isabelle ^a  

^a INSERM   (France)

^b CNRS   (France)

^c University of Montpellier I and II   (France)

^d CENTRE VAL D AURELLE   (France)

Author keywords

Anti idiotypic vaccine; HER2; Llama antibodies

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; SINGLE DOMAIN ANTIBODY 1HE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; BAGG ALBINO MOUSE; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; CAMELIDS, NEW WORLD; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; OVUM; PEPTIDE LIBRARY; RECEPTOR, ERBB-2;

EID: 67650236125     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.067     Document Type: Article

References (40)

1. Kern F.G., Cheville A.L., and Liu Y.L. Growth factor receptors and the progression of breast cancer. Semin Cancer Biol 1 (1990) 317-328
2. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50 (1990) 4087-4091
3. Tewari K.S., Kyshtoobayeva A.S., Mehta R.S., Yu I.R., Burger R.A., DiSaia P.J., et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 78 (2000) 130-136
4. Fendly B.M., Winget M., Hudziak R.M., Lipari M.T., Napier M.A., and Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50 (1990) 1550-1558
5. Pegram M.D., Pauletti G., and Slamon D.J. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52 (1998) 65-77
6. Baselga J. Phase I and II clinical trials of trastuzumab. Ann Oncol 12 Suppl. 1 (2001) S49-S55
7. Winer E.P., and Burstein H.J. New combinations with Herceptin in metastatic breast cancer. Oncology 61 Suppl. 2 (2001) 50-57
8. Slamon D.J., Romond E.H., and Perez E.A. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol 4 Suppl. 1 (2006) 4-9 [discussion Suppl. 10, quiz 2 p following Suppl. 10]
9. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 232 (2006) 123-138
10. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (1999) 2639-2648
11. Bengala C., Zamagni C., Pedrazzoli P., Matteucci P., Ballestrero A., Da Prada G., et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 94 (2006) 1016-1020
12. Disis M.L., Calenoff E., McLaughlin G., Murphy A.E., Chen W., Groner B., et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54 (1994) 16-20
13. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., and Eberlein T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92 (1995) 432-436
14. Curigliano G., Spitaleri G., Pietri E., Rescigno M., de Braud F., Cardillo A., et al. Breast cancer vaccines: a clinical reality or fairy tale?. Ann Oncol 17 (2006) 750-762
15. Lollini P., De Giovanni C., Pannellini T., Cavallo F., Forni G., and Nanni P. Cancer immunoprevention. Future Oncol 1 (2005) 57-66
16. Bhattacharya-Chatterjee M., Chatterjee S.K., and Foon K.A. Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther 2 (2002) 869-881
17. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 125C (1974) 373-389
18. Mittelman A., Chen Z.J., Liu C.C., Hirai S., and Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res 54 (1994) 415-421
19. De Cerio A.L., Zabalegui N., Rodríguez-Calvillo M., Inogés S., and Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 26 (2007) 3594-3602
20. Evans S.V., Rose D.R., To R., Young N.M., and Bundle D.R. Exploring the mimicry of polysaccharide antigens by anti-idiotypic antibodies. The crystallization, molecular replacement, and refinement to 2.8 A resolution of an idiotope-anti-idiotope Fab complex and of the unliganded anti-idiotope Fab. J Mol Biol 241 (1994) 691-705
21. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., et al. Naturally occurring antibodies devoid of light chains. Nature 363 (1993) 446-448
22. Alvarez-Rueda N., Leprieur S., Clémenceau B., Supiot S., Sébille-Rivain V., Faivre-Chauvet A., et al. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen. Clin Cancer Res 13 (2007) 5613s-5620s
23. Behar G., Sibéril S., Groulet A., Chames P., Pugnière M., Boix C., et al. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 21 (2008) 1-10
24. Dumoulin M., Conrath K., Van Meirhaeghe A., Meersman F., Heremans K., Frenken L.G.J., et al. Single-domain antibody fragments with high conformational stability. Protein Sci 11 (2002) 500-515
25. Dolk E., van Vliet C., Perez J.M.J., Vriend G., Darbon H., Ferrat G., et al. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen. Proteins 59 (2005) 555-564
26. Desmyter A., Decanniere K., Muyldermans S., and Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem 276 (2001) 26285-26290
27. Nguyen V.K., Desmyter A., and Muyldermans S. Functional heavy-chain antibodies in Camelidae. Adv Immunol 79 (2001) 261-296
28. Cortez-Retamozo V., Lauwereys M., Hassanzadeh Gh G., Gobert M., Conrath K., Muyldermans S., et al. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98 (2002) 456-462
29. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31 (2003) 3497-3500
30. Lefranc M.P., Giudicelli V., Kaas Q., Duprat E., Jabado-Michaloud J., Scaviner D., et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res 33 (2005) D593-D597
31. Coelho M., Gauthier P., Pugnière M., Roquet F., Pèlegrin A., and Navarro-Teulon I. Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br J Cancer 90 (2004) 2032-2041
32. Yousfi Monod M., Giudicelli V., Chaume D., and Lefranc M.P. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics 20 Suppl. 1 (2004) i379-i385
33. Zarebski L.M., Urrutia M., and Goldbaum F.A. Llama single domain antibodies as a tool for molecular mimicry. J Mol Biol 349 (2005) 814-824
34. Yan S., Gawlak G., Makabe K., Tereshko V., Koide A., and Koide S. Hydrophobic surface burial is the major stability determinant of a flat, single-layer beta-sheet. J Mol Biol 368 (2007) 230-243
35. Geysen H.M., Rodda S.J., and Mason T.J. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol Immunol 23 (1986) 709-715
36. Cho H., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
37. Garrett J.T., Rawale S., Allen S.D., Phillips G., Forni G., Morris J.C., et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 178 (2007) 7120-7131
38. Riemer A.B., Klinger M., Wagner S., Bernhaus A., Mazzucchelli L., Pehamberger H., et al. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 173 (2004) 394-401
39. Riemer A.B., Kraml G., Scheiner O., Zielinski C.C., and Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol Immunol 42 (2005) 1121-1124
40. Koide A., Tereshko V., Uysal S., Margalef K., Kossiakoff A.A., and Koide S. Exploring the capacity of minimalist protein interfaces: interface energetics and affinity maturation to picomolar KD of a single-domain antibody with a flat paratope. J Mol Biol 373 (2007) 941-953